论文部分内容阅读
目的:探讨拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床效果。方法:选取2013年7月-2015年1月我院收治的失代偿期乙型肝炎肝硬化患者,共计90例。均分为观察组和对照组,各45例,观察组患者采用拉米夫定联合阿德福韦酯联合方案治疗,对照组患者采用临床常规治疗,对比各自疗效情况。结果:观察组中随访两年后生存37例,比例为82.2%,对照组为26例,比例为57.8%,对比发现观察组在生存情况方面优于对照组,差异具有统计学意义(P<0.05)。在Child-Pugh分级方面,观察组37例B级,18例C级;对照组24例B级,21例C级,对比发现两组患者差异无统计学意义(P>0.05)。对ALT含量进行统计发现,观察组为27.3 U/L,对照组为36.5 U/L,对比发现观察组显著优于对照组,差异具有统计学意义(P<0.01)。结论:拉米夫定联合阿德福韦酯是一种有效治疗失代偿期乙型肝炎肝硬化的药物方案,该方法治疗效果显著,临床治疗过程中未发现严重不良反应。
Objective: To investigate the clinical effect of lamivudine combined with adefovir dipivoxil on decompensated hepatitis B cirrhosis. Methods: Totally 90 patients with decompensated hepatitis B cirrhosis admitted in our hospital from July 2013 to January 2015 were selected. The observation group and the control group were divided into observation group and control group, 45 cases in each group. The observation group was treated with lamivudine combined with adefovir dipivoxil, and the control group was treated by routine clinical treatment. Results: In the observation group, 37 cases survived two years later, with a proportion of 82.2% and a control group of 26 cases (57.8%). The observation group was superior to the control group in survival status with statistical significance (P < 0.05). In the Child-Pugh grading, the observation group had 37 cases of grade B and 18 cases of grade C; the control group had 24 cases of grade B and 21 cases of grade C, and there was no significant difference between the two groups (P> 0.05). The ALT content was statistically observed, the observation group was 27.3 U / L, the control group was 36.5 U / L, compared with the observation group was significantly better than the control group, the difference was statistically significant (P <0.01). Conclusions: Lamivudine combined with adefovir dipivoxil is an effective drug for the treatment of decompensated hepatitis B cirrhosis. The treatment is effective and no serious adverse reactions are found during the course of clinical treatment.